GYREMEDIUM SIGNALFINANCIAL10-K

GYRE shows strong capital raise and operational improvement with cash increasing 214% and turning cash flow positive, though net income declined 45% despite 10x revenue growth.

The company appears to have completed a significant financing round, evidenced by the substantial increase in cash and stockholders' equity, while simultaneously improving operational efficiency by achieving positive operating cash flow. However, the dramatic decline in net income despite strong revenue growth suggests either one-time charges or increasing operational costs that warrant closer examination.

Comparing 2026-03-13 vs 2025-03-17View on EDGAR →
FINANCIAL ANALYSIS

GYRE demonstrated mixed but generally positive financial momentum, with revenue surging 10x to $275K and operating cash flow turning positive at $1.0M from negative $3.6M, indicating improved operational efficiency. The company significantly strengthened its balance sheet through what appears to be a major capital raise, boosting cash reserves 214% to $37.1M and stockholders' equity 68% to $106.0M. Despite these positives, net income dropped 45% to $9.9M and interest expense spiked over 6,300% to $1.5M, suggesting either increased debt obligations or one-time charges that investors should monitor closely.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+6326.1%
$23K$1.5M

Interest expense surged 6326.1% — significant debt increase or rising rates materially impacting earnings.

Revenue
P&L
+1000%
$25K$275K

Strong top-line growth of 1000% — accelerating demand or successful expansion into new markets.

Cash & Equivalents
Balance Sheet
+213.8%
$11.8M$37.1M

Cash position surged 213.8% — strong cash generation or capital raise providing significant financial cushion.

Operating Cash Flow
Cash Flow
+127.7%
-$3.6M$1.0M

Operating cash flow surged 127.7% — exceptional cash generation, highest quality earnings signal.

Stockholders Equity
Balance Sheet
+67.5%
$63.3M$106.0M

Equity base grew 67.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Accounts Receivable
Balance Sheet
+58.7%
$19.6M$31.1M

Receivables surged 58.7% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Current Assets
Balance Sheet
+58%
$64.8M$102.4M

Current assets grew 58% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
-48.6%
$2.3M$1.2M

Capex reduced 48.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Inventory
Balance Sheet
+48%
$4.3M$6.3M

Inventory surged 48% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

Net Income
P&L
-44.8%
$17.9M$9.9M

Net income declined 44.8% — review whether driven by operations, interest costs, or non-recurring items.

LANGUAGE CHANGES
NEW — 2026-03-13
PRIOR — 2025-03-17
ADDED
As of March 2, 2026, the number of outstanding shares of the registrant s common stock, par value $0.001 per share, was 96,963,611 , which includes 5,649,604 shares of common stock issued in the name of the registrant to a stock plan administrator of the registrant (see Note 8 Stockholders Equity).
Overview We are a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases.
We operate through our majority indirectly owned subsidiary, Gyre Pharmaceuticals, in the PRC, and through our U.S.
In the PRC, we have established a strong commercial and operational foundation in fibrotic diseases through the successful development and commercialization of ETUARY (pirfenidone), which has generated consistent revenue and positioned us as a leading participant in the treatment of pulmonary fibrosis.
Fibrotic diseases affect large patient populations worldwide and involve complex, multi-stage biological processes driven by multiple molecular pathways.
+7 more — sign up free →
REMOVED
As of March 7, 2025, the number of outstanding shares of the registrant s common stock, par value $0.001 per share, was 93,612,442 , which includes 7,280,230 shares of common stock issued in the name of the registrant to a stock plan administrator of the registrant (see Note 8 Stockholders Equity).
Overview We are a commercial-stage pharmaceutical company with a proven track record of financial success developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis.
Fibrotic diseases represent a large patient population with significant unmet medical needs and involve complex, multi-stage processes with multiple pathways.
While there are numerous potential targets for anti-fibrotic therapy, both established and emerging, addressing a single molecular pathway may not be sufficient to prevent, halt, or reverse fibrosis.
Our strategy is to build on our success in the development and commercialization of ETUARY (pirfenidone) to expand into new indications and advance our pipeline of innovative drug candidates.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →